Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacodynamic Evaluation of Intranasal Nalmefene
NCT04828005Phase 1Completed
- Sponsor
- Opiant Pharmaceuticals
- Start
- Mar 2021
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of nalmefene in opioid overdose (2 arms), sponsored by Opiant Pharmaceuticals. Primary endpoint: Change in Minute Ventilation at 5 minutes. Started Mar 2021; status: completed.
02
Drugs
nalmefene
03
Conditions
opioid overdose
Beyond the preview
Go deeper on NCT04828005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04828005.